PDCD1LG2 and melanoma: Importantly, the presence of PD‐L2+EVs during anti‐PD‐1 therapy reflects a tumour that is more responsive to ICI‐based therapies, making EV membrane PD‐L2 a potential predictive marker for therapeutic efficacy in melanoma patients.